Related Experiment Videos
Detection of P-glycoprotein in solid tumors by flow cytometry
H Fujii1, N Tanigawa, R Muraoka
1Second Department of Surgery, Fukui Medical School, Japan.
Anticancer Research
|November 1, 1993
Summary
Flow cytometry effectively detects P-glycoprotein (P-gp), correlating with drug resistance in cancer cells and human carcinomas. This method accurately predicts tumor sensitivity to chemotherapy agents like doxorubicin and vincristine.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- P-glycoprotein (P-gp) is a key efflux pump contributing to multidrug resistance (MDR) in cancer.
- Accurate detection of P-gp is crucial for predicting treatment response.
Purpose of the Study:
- To evaluate the efficacy of flow cytometry (FCM) for P-gp detection.
- To correlate FCM-based P-gp detection with established methods and clinical drug resistance.
Main Methods:
- Flow cytometry (FCM) was used to detect P-gp in K562 cell lines and human carcinomas.
- Results were compared with immunohistochemical staining, Western blotting, and thymidine incorporation assays (TIA).
Main Results:
- FCM showed strong correlation with P-gp detection by immunohistochemistry and Western blotting.
- FCM data strongly correlated with doxorubicin resistance assessed by TIA.
- 37.5% of tested human carcinomas were P-gp positive by FCM.
- P-gp positive tumors demonstrated resistance to doxorubicin and vincristine.
Conclusions:
- Flow cytometry is a reliable method for detecting P-glycoprotein.
- FCM-based P-gp detection strongly correlates with tumor drug resistance and can predict sensitivity to doxorubicin and vincristine.